MPC6

MPC6 (Multivalent Peptoid Conjugate 6) is a multivalent peptoid conjugate designed to treat advanced, enzalutamide-resistant prostate cancer. It consists of a peptoid oligomer backbone presenting two spatially defined ethisterone ligands as pendant groups. MPC6 functions by disrupting the interaction between the androgen receptor (AR) and its coactivators and by promoting the degradation of the AR protein, thereby reducing its half-life. In preclinical studies, MPC6 demonstrated metabolic stability, low plasma clearance, and the ability to suppress the proliferation of multiple AR-expressing prostate cancer cell lines, including those resistant to enzalutamide and ARN509. It has also shown efficacy in reducing tumor growth and decreasing AR expression in mouse xenograft models of treatment-resistant prostate cancer.